新型口服药物治疗肥厚型心肌病前后的超声变化  

Echocardiographic Changing Pattern in Treatment of Hypertrophic Cardiomyopathy with A Novel Oral Drug

作　　者：孔令云 张睿[1] 吕婷婷 向伟 王秀娟[1] 陈玲玲 刘芳[1] Kong Lingyun;Zhang Rui;Lyu Tingting;Xiang Wei;Wang Xiujuan;Chen Lingling;Liu Fang(Department of Cardiology,Beijing Tsinghua Changgung Hospital,School of Clinical Medicine,Tsinghua University,Beijing 102218,China)

机构地区：[1]清华大学附属北京清华长庚医院心内科,清华大学临床医学院,北京市102218

出　　处：《中国超声医学杂志》2023年第5期596-599,共4页Chinese Journal of Ultrasound in Medicine

摘　　要：肥厚型心肌病(HCM)是一种以心室肥厚和梗阻为主要特征的常染色体显性遗传性心肌病。超声心动图是最常用的诊断和评估手段。新近问世的心脏肌球蛋白抑制剂——Mavacamten在多个临床试验中显示出逆转左室肥厚和减轻左室梗阻的效果,有望成为同类首个可口服的治疗HCM的靶向药物。本研究总结了Mavacamten治疗HCM前后超声心动图的变化特点。Hypertrophic cardiomyopathy(HCM)was a genetic heart disease characterized by ventricular hypertrophy and intracavitary obstruction.Echocardiography had been the imaging technique of choice for diagnosis and evaluation of HCM.The newly advent myosin inhibitor-mavacamten,has shown promise for reversal of myocardial hypertrophy and obstruction in multiple clinical trials,and may become the first-in-class oral administration targeted for HCM.This review summarizes the echocardiographic changes with treatment of HCM with mavacamten。

关 键 词：肥厚型心肌病 心室肥厚 口服药物治疗 超声心动图 逆转左室肥厚 临床试验 靶向药物 心脏肌球蛋白 

分 类 号：R445.1[医药卫生—影像医学与核医学] R542.2[医药卫生—诊断学]